Clinical Trials & Cancer Research

About cCARE’s cancer research

cCARE is proud to offer numerous institutional-grade clinical trials for cancer patients. Clinical trials assess new drug or treatment effectiveness and provide cancer patients with the newest – and possibly most effective – forms of treatment.

Cancer clinical trials are divided into three different phases. Phase I trials assess the safety of a drug or treatment; phase II trials quantify how effective the treatment is while phase III compares the trial to the best existing cancer treatment.

The decision to participate in a clinical trial should be made early in the diagnosis stage because once treatment begins, patients may not be eligible to participate in certain clinical trials. Benefits of participating in clinical trials include access to the newest treatment and medicine designed to fight your particular type of cancer as well as being monitored closely throughout the treatment process.

Although clinical trials provide many benefits, patients must consider the risks as well. Participants may experience unforeseen side effects, the treatment may just not work as well as previous methods and health insurance coverage may not extend to participating in a trial. Speak with your oncologist about whether or not a clinical trial is right for your specific case.

Open clinical trials at cCARE

Below is a list of clinical trials currently open at cCARE. If you have any questions please call us at (760) 452-3909 or email Beth Kimball, RN OCN, Clinical Study Coordinator and Program Lead, at [email protected].

Research contact centers

Phone: (760)-452-3909

cCARE San Diego – Escondido
Mona Bilawa
[email protected]

cCARE San Diego – Encinitas
Beth Kimball, RN, OCN
[email protected]

cCARE Fresno
Cheryl Jarman
[email protected]

 

 

San Diego cancer clinical trials – (jump to Fresno clinical trials)

Gastric Cancer Clinical Trail

Title: Avelumab in First-Line Gastric Cancer

The purpose of this study is to demonstrate superiority of treatment with Avelumab versus continuation of first-line chemotherapy.

Learn More About This Cancer Study


Metastatic Renal Cell Carcinoma Clinical Trial

Title: A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

The purpose of this study is to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.

Learn More About This Cancer Study


Hepatocellular Carcinoma, Renal Cell Carcinoma, Melanoma & Prostate Adenocarcinoma Clinical Trial

Title: Recombinant Human Arginase 1 (rhArg1) in Patients with Advanced Arginine Auxotrophic Solid Tumors

The goal of this clinical research study is to evaluate the safety of PEG-BCT-100 given as an infusion to treat patients who bear advanced solid tumors that are dependent on arginine (melanoma, renal cell carcinoma, prostate cancer and hepatocellular carcinoma), and who have progressed after receiving approved or established therapies.

Learn More About This Cancer Study


Colorectal & Breast Cancer Clinical Trial

Title: Safety and Tolerability Study in Solid Tumors

This is an open-label, multicenter, sequential dose-escalation, and expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GS-5745 alone and in combination with chemotherapy.

Learn More About This Cancer Study


Cancer Tumors Clinical Trial

Title: MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means the study drug has not previously been given to humans or has only been given to a limited number of people, although it has been extensively studied in animals.

Learn More About This Cancer Study


Solid Tumors, Non-Small Cell Lung, Biliary & Bladder Cancer Clinical Trial

Title: Combination Therapy with NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

In the dose escalation phase (Part 1), this study will determine the dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) and recommended Phase 2 (RPII) dose of NC 6004 in combination with gemcitabine.

Learn More About This Cancer Study


Glioblastoma Multiforme Clinical Trial

Title: A Feasibility Study of the Nativis Voyager System in Patients with Recurrent Glioblastoma Multiforme (GBM)

This feasibility study will assess the effects of the Nativis Voyager therapy in patients with recurrent GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to 64 subjects of which 32 will be treated with the Voyager therapy alone (monotherapy) and 32 will be treated with Voyager plus concurrent chemotherapy.

Learn More About This Cancer Study


Metastatic Castrate Resistant Prostate Cancer Clinical Trial

Title: Phase III Study of DCVAC Added to Standard Chemotherapy for Men with Metastatic Castration Resistant Prostate Cancer (VIABLE)

The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care Chemotherapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer.

Learn More About This Cancer Study


Multiple Myeloma Clinical Trial

Title: Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma.

Learn More About This Cancer Study


Multiple Myeloma Clinical Trial

Title: Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

The purpose of this Phase II study is to evaluate the safety and effectiveness (good and bad effects) of carfilzomib given as a 30-minute infusion and at a dose of 70 mg/m2 to treat patients with multiple myeloma (MM), who are currently showing progressive disease (worsening) and had progressed (did not respond to treatment) within 8 weeks of receiving treatment with 27mg/m2 of carfilzomib.

Learn More About This Cancer Study


Multiple Myeloma Clinical Trial

Title: Pomalidomide for Lenalidomide for Failures

The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM).

Learn More About This Cancer Study


Lymphoma Clinical Trial

Title: Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cellLymphoma (ROBUST)

To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL.

Learn More About This Cancer Study


Non-Small Cell Lung Cancer Clinical Trial

Title: Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients with Lung Cancer [IMpower010]

A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer.

Learn More About This Cancer Study


Non-Squamous Non-Small Cell Lung Cancer Clinical Trial

Title: A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130]

This randomized Phase III, multicenter, open-label study is designed to evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with carboplatin + Nab-paclitaxel compared with treatment with carboplatin + Nab-paclitaxel in chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).

Learn More About This Cancer Study


Hepatocellular Carcinoma Clinical Trial

Title: A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608 in combination with sorafenib, or BBI503 in combination with sorafenib. The study population is adult patients with advanced hepatocellular carcinoma who have not received systemic chemotherapy.

Learn More About This Cancer Study


Lung Cancer Clinical Trial

Title: Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab

This is a phase 1b study evaluating a combination of PEGPH20 and pembrolizumab for subjects with relapsed/refractory advanced or metastatic Non Small Cell Lung Cancer (NSCLC) who have failed at least 1 platinum-based chemotherapy regimen and subjects with relapsed/refractory locally advanced or metastatic gastric adenocarcinoma after failing at least 1 chemotherapy regimen.

Learn More About This Cancer Study

Fresno cancer clinical trials – (jump to San Diego clinical trials)

Metastatic Colorectal Cancer Clinical Trial

Title: A Phase III Study of Xilonix in Patients with Advanced Colorectal Cancer (XCITE)

The purpose of this study is to determine if the True Human Monoclonal antibody Xilonix (MABp1) can prolong the life of colorectal carcinoma patients that are refractory to standard therapy.

Learn More About This Cancer Study


Multiple Myeloma Clinical Trials

Title: Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma.

Learn More About This Cancer Study


Colorectal Cancer & Breast Cancer Clinical Trial

Title: Safety and Tolerability Study in Solid Tumors

This is an open-label, multicenter, sequential dose-escalation, and expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GS-5745 alone and in combination with chemotherapy.

Learn More About This Cancer Study